Exciting Scientific Biomarker Lead position in an innovative biopharmaceutical company
Nykode Therapeutics is seeking a dynamic and innovative Scientific Biomarker Lead to join the biomarker and translational research team.
You will be a core member of the clinical development teams, responsible for planning and leading all clinical pharmacodynamic and biomarker activities for Nykode’s lead candidate VB10.16.
Responsibilities include:
Your qualifications include a minimum of 4 years of experience in drug development in a clinical stage biotech. Your experience spans across immuno-oncology, clinical immunology, translational medicine activities, and biomarker research. You possess adeptness in collaborating with contract research organizations and academic partners. Proficiency in companion diagnostics/IVD is considered highly advantageous.
You have a PhD degree within medical, biological, or pharmaceutical science or equivalent.
You are meticulous with an analytical mindset. Proficient in problem-solving and effective in proactively integrating cross-functional information for workflow enhancement within diverse teams. You are known as a resilient team player skilled at nurturing cooperation in dynamic environments, cultivating trust through open communication, feedback, and motivation.
Nykode Therapeutics offers an opportunity to be a highly visible member of clinical development project team, where you will have room to influence your role and enhance your skills in clinical development strategy of oncology vaccines.
Nykode is looking for individuals who are inspired by the Nykode technology and the quest to unlock the future of medicine. Nykode is eager to hire people who seek out environments that offer creative challenges and provide growth opportunities.
Travelling: Limited.
Domicile: Oslo Norway, or Copenhagen, Denmark.
For more details about the job or the company, please contact Director Gert Vium Andersen, Unique Human Capital, on mobile: +45 42 95 08 83. All applications must be in English and are treated confidentially.
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.
Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.
The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.
Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Read more at https://nykode.com/
We are more than 200 people who work with knowledge, creativity and technology
